Categories
Latest News Marketing Videos

ETST 2017 year in review

Categories
In the News Latest News Marketing Press Releases Top Stories

Earth Science Tech Signs Distribution Agreement with Mr. Checkout for its New CBD Product Revamp Starting in 2018

Doral, FL, Dec. 13, 2017 (GLOBE NEWSWIRE) — Earth Science Tech (OTC PINK:ETST) (“ETST” or “the Company”), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, signs distribution agreement with Mr. Checkout, beginning in 2018, and coinciding with the company’s new CBD product revamp.

ETST looks to start the year strong, adding it’s first major distributor to the already strong and growing team of representatives across the U.S. The company currently has 10 active representatives opening and managing accounts across the states, one of which recently joined in December and immediately began bringing in a good number of chain stores. The representatives have been very successful with health food stores and clinics. ETST has signed a distribution agreement with Mr. Checkout to open and manage major retailers and stores within the U.S., which substantially expands the company’s reach.

Mr. Checkout, as featured on ABC’s Shark Tank, is a national group of independent distributors, full-line grocery distributes, and convenience stores. Mr. Checkout represents products in over 60 major retailers throughout the U.S. and approximately 55,000 stores. A few of Mr. Checkout’s accounts are Walgreens, CVS, Walmart, Wholefoods Market, and Target, just to name a few.

Gabriel Aviles, ETST’s Chief Sales Officer & Director states, “I feel that we have finally put together a solid productive team of representatives that we needed to continue expanding our presence in health shops and clinics. Now, with Mr. Checkout, we will be able to take our presence and sales to the next level, entering larger retailers and many stores. 2018 looks to be starting off very strong with our new product revamp, marketing and education strategy, and sales channel.”

ETST’s President, Director, & COO concludes with, “Gabriel has done a remarkable job building our sales team and expanding our presence across the U.S. I have no doubt that 2018 is going to be a solid year of growth for us, with all we have initiating as early as January alone, with our CBD products. Our MSN-2 medical device globalization strategy is still on track, and we are currently in talks with institutional investors thanks to our planned up-listing in Q1 2018. I plan on sharing further updates as they progress on the MSN-Medical deviceIP patentsCBD based pharmaceutical generic drugs, and our new CBD formula opioid clinical trials as they progress.”

 

About Earth Science Tech (ETST)

Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world’s best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil.

To learn more and to buy CBD Hemp Oil please visit: www.earthsciencetech.com

View ETST’s accomplishments and reports on its High-Grade CBD Hemp Oil: (here)

 

About Earth Science Pharmaceutical

Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit: www.Earthsciencepharmaceutical.com

 

About Cannabis Therapeutics

Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit: www.Cannabisthera.com

 

About KannaBidioiD

KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by it’s unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit: www.kannabidioidinc.com

 

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

 

SAFE HARBOR ACT

Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Dave Demarest (305)-546-7640

Earth Science Tech Nickolas S. Tabraue, P/D/COO (305)-615-2118
Categories
Hemp Oil In the News Latest News Marketing Press Releases Top Stories

ETST is starting the new year with a revamped CBD product packaging and marketing.

The ETST marketing team is always looking to keep our product marketing fresh and relevant in the current CBD market. Our team recently announced that it will steer the company’s branding in a new direction. Instead of labeling and marketing its products as, “High-Grade Hemp CBD Oil,” the company will start branding and marketing its products as, “High Grade Full Spectrum Cannabinoids,” in the beginning of 2018.

Our design team also has worked on new packaging designs for our line of products. The new designs kept the familiar blue and white color schemes but cleaned up the layout and added some detailed splash elements and icons to bring the design together.

See the designs below

 

 

ETST’s Chief Marketing Officer commented, “We did a lot of market research to see what the best angle to truly stand out in the growing CBD industry is through our accounts, representative feedback, and external brand analysis. I feel that marketing, HHigh-GradeFull Spectrum Cannabinoids’ will help ETST truly stand out. Soon, the market will be able to see that ETST is a true full spectrum CBD brand, especially with the cannabinoid complex listing under the supplement facts.”

Categories
Gonorrhea Latest News Marketing Medical Press Releases Sexually Transmitted Infections

ETST:Negotiations underway for MSN-2 and Nanoderm distribution in three countries and plans new clinical study with HIV- seropositive and AIDS patients

Doral, FL, Nov. 30, 2017 (GLOBE NEWSWIRE) — Earth Science Tech (OTC PINK: ETST) (“ETST” or “the Company”), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, updated share holders on medical devices  promotion and plans to launch a clinical study with HIV-seropositive and AIDS patients

As previously announced, ETST will initiate the distribution of its medical devices in Djibouti and Morocco (http://www.otcmarkets.com/stock/ETST/news/Earth-Science-Tech–Inc–Announces-New-Agreement-with-Axcelon-Biopolymers-Corp–for-Distribution-of-Nanoderm-trade–Medical-Device–amp–Advances-with-Its-MSN-2-Medical-Device?id=170151&b=y ) while the company waits for regulatory permission to launch in North America.  ETST announces an imminent partnership agreement to develop the Vietnam market for the MSN-2 medical device (branding with original name and graphic environment is coming soon (http://www.otcmarkets.com/stock/ETST/news/Earth-Science-Tech–Inc–Signs-Contract-with-Absolu-to-Advance-Phase-2-Rollout-on-MSN-2-Medical-Device?id=166272&b=y ) and the Nanoderm™ medical device which was developed by a member of the ETST advisory board, Dr. Chandra Panchal (Founder, Chairman, Chief Executive Officer and Chief Scientific Officer of Axcelon Biopolymer: http://axcelonbp.com/companay/board-of-directors/ ). Only some details remain to be discussed and the new Vietnam market partner will be announced in the before year end.

The company is also in discussion to introduce its high-grade CBD hemp oil in the primary launch countries. The first samples of MSN-2 and Nanoderm™ are being sent to those three countries, Djibouti, Morocco and Vietnam, in order to start negotiations with local authorities and partners.

In Vietnam the products will be presented directly to hospital administrators and physicians by ETST’s new American partner who is of Vietnamese origin. This partner, whose name will be announced officially in a few days, has been a distributor of medical devices for many years and saw a huge opportunity working with us.

New clinical study of HIV seropositive and AIDS-infected patients

ETST is planning a clinical study of HIV-seropositive people and AIDS-infected patients in the hope of making as much a difference in the lives of as many people as is possible. The company sees a very good opportunity to help people that are infected with HIV because they suffer from oxidative- related stress and inflammation that are caused by their medical condition. Many HIV patients suffer from chronic pain that requires them to take opioids, or are addicted to opioids. ETST’s CBD rich hemp oil may help them to diminish the quantity of pain relief drugs they need to take and help with the withdrawal from opioids. This project is in line with the clinical study that was just announced this week (http://www.otcmarkets.com/stock/ETST/news/Earth-Science-Tech-Commences-Pre-Launch–Double-Blind-Human-Clinical-Trials-for-New-CBD-Formula-to-Fight-U-S–Opioid-Epidemic?id=176428&b=y ).

In addition, HIV patients are often afflicted by neurological complications that originate from neuro-inflammation. The neuronal protection activity of ETST CBD rich hemp oil has already been proven in vitro by DV Biologics:

http://www.otcmarkets.com/stock/ETST/news/DV-Biologics–a-Leading-Biological-Company–Reports-Earth-Science-Tech–ETST–High-Grade-Hemp-CBD–Cannabidiol–Oil-Reduces-Oxidative-Stress-and-Lipid-Peroxidation-on-Human-Brain-Cells-In-Vitro?id=107954&b=y

The administration of CBD may not only relieve many symptoms resulting from HIV infection and associated medication, but it may also help to retard the development of other HIV-associated diseases. This clinical assay will lay the foundation for the creation of the first CBD rich Hemp Oil product improved with other natural molecules to relieve symptoms and retard diseases in HIV patients.

Further updates concerning the third clinical study and other ETST projects will be issued soon.

 

About Earth Science Tech (ETST)

Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world’s best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil.

To learn more and to buy CBD Hemp Oil please visit: www.earthsciencetech.com

View ETST’s accomplishments and reports on its High-Grade CBD Hemp Oil: (here)

 

About Earth Science Pharmaceutical

Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit: www.Earthsciencepharmaceutical.com

 

About Cannabis Therapeutics

Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit: www.Cannabisthera.com

 

About KannaBidioiD

KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by it’s unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit: www.kannabidioidinc.com

 

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

 

SAFE HARBOR ACT

Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

 

Investor Relations Dave Demarest (305)-546-7640

Earth Science Tech Nickolas S. Tabraue, P/D/COO (305)-615-2118